|
EP0866805A1
(en)
|
1995-12-12 |
1998-09-30 |
Karolinska Innovations AB |
PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
|
|
EP0938571B8
(en)
*
|
1996-10-28 |
2008-07-02 |
University of Lausanne |
Method for the oligomerisation of peptides
|
|
US6924123B2
(en)
|
1996-10-29 |
2005-08-02 |
Oxford Biomedica (Uk) Limited |
Lentiviral LTR-deleted vector
|
|
GB9622500D0
(en)
*
|
1996-10-29 |
1997-01-08 |
Oxford Biomedica Ltd |
Therapeutic gene
|
|
GB2333527B
(en)
*
|
1996-10-29 |
2001-05-02 |
Oxford Biomedica Ltd |
Therapeutic gene
|
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
EP0979281B1
(en)
|
1997-05-02 |
2005-07-20 |
Genentech, Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
|
WO1998056906A1
(en)
*
|
1997-06-11 |
1998-12-17 |
Thoegersen Hans Christian |
Trimerising module
|
|
US6737252B2
(en)
|
1997-07-25 |
2004-05-18 |
Schering Corporation |
7 transmembrane receptor family member BLRX
|
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US6905686B1
(en)
|
1997-12-02 |
2005-06-14 |
Neuralab Limited |
Active immunization for treatment of alzheimer's disease
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US7179892B2
(en)
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
|
GB9809280D0
(en)
*
|
1998-04-30 |
1998-07-01 |
Rpms Technology Ltd |
Immunosupression
|
|
US7083950B2
(en)
|
1998-09-25 |
2006-08-01 |
Regeneron Pharmaceuticals, Inc. |
High affinity fusion proteins and therapeutic and diagnostic methods for use
|
|
US20030035798A1
(en)
*
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
|
PL199645B1
(pl)
*
|
1998-12-23 |
2008-10-31 |
Regeneron Pharma |
Kwas nukleinowy, polipeptyd fuzyjny, kompozycja, wektor, wektor ekspresyjny, układ gospodarz wektor, sposób wytwarzania polipeptydu fuzyjnego, kwas nukleinowy i sposób wytwarzania polipeptydu fuzyjnego
|
|
WO2000044908A2
(en)
*
|
1999-02-01 |
2000-08-03 |
Beth Israel Deaconess Medical Center |
Comp/tsp-1, comp/tsp-2 and other tsp chimeric proteins
|
|
GB9903408D0
(en)
*
|
1999-02-15 |
1999-04-07 |
Oxford Biomedica Ltd |
Peptides
|
|
US6828106B2
(en)
*
|
1999-02-26 |
2004-12-07 |
Cyclacel Limited |
Methods and compositions using coiled binding partners
|
|
US7060670B1
(en)
|
1999-05-05 |
2006-06-13 |
Neurochem (International) Limited |
Stereoselective antifibrillogenic peptides and peptidomimetics thereof
|
|
JP2003502024A
(ja)
*
|
1999-05-14 |
2003-01-21 |
メディカル リサーチ カウンシル |
タンパク質骨格および単量体ポリペプチドを多量体化するためのその使用
|
|
CA2372199A1
(en)
*
|
1999-05-14 |
2000-11-23 |
Medical Research Council |
Oligomeric chaperone proteins
|
|
US7087411B2
(en)
*
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
PE20020574A1
(es)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
|
CA2440235A1
(en)
*
|
2001-03-06 |
2002-09-12 |
Mustapha Abdelouahed |
Carrier chimeric proteins, targeted carrier chimeric proteins and preparation thereof
|
|
PT1390535E
(pt)
*
|
2001-04-26 |
2010-10-04 |
Amgen Mountain View Inc |
Bibliotecas combinatórias de domínios monoméricos
|
|
JP3563366B2
(ja)
*
|
2001-05-07 |
2004-09-08 |
独立行政法人 科学技術振興機構 |
蛋白質高次構造に対してアンフォールド活性を有する蛋白質多量体
|
|
IL159177A0
(en)
|
2001-06-20 |
2004-06-01 |
Prochon Biotech Ltd |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
AU2002349204A1
(en)
*
|
2001-11-26 |
2003-06-10 |
University Health Network |
Self-assembling p53 peptides as gene delivery vehicles
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
AU2003239777A1
(en)
*
|
2002-07-05 |
2004-01-23 |
Borean Pharma A/S |
Multimerised growth hormone fusion proteins
|
|
PE20050627A1
(es)
|
2003-05-30 |
2005-08-10 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido beta amiloideo
|
|
FR2856070A1
(fr)
*
|
2003-06-13 |
2004-12-17 |
Bionexis |
Molecules pour le ciblage et l'assemblage in situ de proteines therapeutiques et leur utilisation
|
|
ES2304812B1
(es)
*
|
2003-12-03 |
2009-10-21 |
Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria (Inia) |
Sistema para producir peptidos y proteinas, multimericos, y sus aplicaciones.
|
|
WO2006021954A2
(en)
|
2004-08-23 |
2006-03-02 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Peptide inhibitors for mediating stress responses
|
|
AR052051A1
(es)
|
2004-12-15 |
2007-02-28 |
Neuralab Ltd |
Anticuerpos ab humanizados usados en mejorar la cognicion
|
|
EP1838854B1
(en)
|
2004-12-15 |
2012-10-31 |
Janssen Alzheimer Immunotherapy |
Antibodies that recognize Beta Amyloid Peptide
|
|
WO2006117782A2
(en)
|
2005-05-04 |
2006-11-09 |
Quark Pharmaceuticals, Inc. |
Recombinant antibodies against cd55 and cd59 and uses thereof
|
|
US20070243584A1
(en)
*
|
2006-04-13 |
2007-10-18 |
West James W |
Tetramerizing polypeptides and methods of use
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
CA2655504A1
(en)
|
2006-06-15 |
2007-12-21 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
JP5889529B2
(ja)
|
2007-07-27 |
2016-03-22 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
アミロイド原性疾患の処置
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
WO2009103826A1
(es)
*
|
2008-02-19 |
2009-08-27 |
Alternative Gene Expression, S.L. |
Sistema para producir péptidos y proteínas, multiméricos, y sus aplicaciones
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
CA3080181A1
(en)
*
|
2011-03-04 |
2012-09-13 |
Shire Human Genetic Therapies, Inc. |
Peptide linkers for polypeptide compositions and methods for using same
|
|
WO2012160563A2
(en)
|
2011-05-23 |
2012-11-29 |
Yeda Research And Development Co. Ltd. |
Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
|
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
|
EP2833900B1
(en)
|
2012-04-01 |
2018-09-19 |
Technion Research & Development Foundation Limited |
Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
|
|
US9243294B2
(en)
|
2013-09-30 |
2016-01-26 |
Hadasit Medical Research Services And Development Ltd. |
Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
|
|
EP3074035B1
(en)
|
2013-11-25 |
2020-05-13 |
FameWave Ltd. |
Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
ME03558B
(me)
|
2014-03-14 |
2020-07-20 |
Novartis Ag |
Molekuli anti-lag-3 antiтela i njihove upotrebe
|
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
US20170174764A1
(en)
|
2014-03-27 |
2017-06-22 |
Yeda Research And Development Co. Ltd. |
T-cell receptor cdr3 peptides and antibodies
|
|
AP2016009504A0
(en)
|
2014-04-27 |
2016-10-31 |
Ccam Biotherapeutics Ltd |
Humanized antibodies against ceacam1
|
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
BR112017001242A2
(pt)
|
2014-07-21 |
2017-12-05 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico a cd33
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
WO2016014565A2
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
US20170209492A1
(en)
|
2014-07-31 |
2017-07-27 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
JP6919118B2
(ja)
|
2014-08-14 |
2021-08-18 |
ノバルティス アーゲー |
ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
|
|
MY189028A
(en)
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
CA2961636A1
(en)
|
2014-09-17 |
2016-03-24 |
Boris ENGELS |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
MX389663B
(es)
|
2014-10-14 |
2025-03-20 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
WO2016157195A1
(en)
|
2015-04-01 |
2016-10-06 |
Hadasit Medical Research Services And Development Ltd. |
Inhibitors of neuroligin 4 - neurexin 1-beta protein-protein interaction for treatment of liver disorders
|
|
IL254817B2
(en)
|
2015-04-08 |
2023-12-01 |
Novartis Ag |
Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
|
US20180222982A1
(en)
|
2015-07-29 |
2018-08-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
ES2924071T3
(es)
|
2015-09-02 |
2022-10-04 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Anticuerpos específicos para inmunoglobulina de células T humanas y dominio ITIM (TIGIT)
|
|
EP3362093A4
(en)
|
2015-10-13 |
2019-05-08 |
Technion Research & Development Foundation Limited |
HEPARANASE-NEUTRALIZING MONOCLONAL ANTIBODIES
|
|
JP2019502695A
(ja)
|
2015-12-17 |
2019-01-31 |
ノバルティス アーゲー |
ＰＤ−１に対する抗体分子とＣ−Ｍｅｔ阻害剤との組合せおよびその使用
|
|
EP3389712B1
(en)
|
2015-12-17 |
2024-04-10 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
|
MA44140A
(fr)
|
2015-12-22 |
2021-05-19 |
Dana Farber Cancer Inst Inc |
Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
|
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
|
MX2018010445A
(es)
|
2016-03-01 |
2019-10-17 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Anticuerpos especificos del receptor de poliovirus humano (rvp).
|
|
CA3016287A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
SI3443096T1
(sl)
|
2016-04-15 |
2023-07-31 |
Novartis Ag |
Sestavki in postopki za selektivno izražanje himerni antigenskih receptorjev
|
|
EP3464375A2
(en)
|
2016-06-02 |
2019-04-10 |
Novartis AG |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
CN120285179A
(zh)
|
2016-07-15 |
2025-07-11 |
诺华股份有限公司 |
使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征
|
|
IL264486B2
(en)
|
2016-07-28 |
2025-04-01 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and PD-1 inhibitors
|
|
SG11201900885VA
(en)
|
2016-08-01 |
2019-02-27 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
EP3512875A2
(en)
*
|
2016-09-15 |
2019-07-24 |
Quadrucept Bio Limited |
Multimers, tetramers&octamers
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
US20200048359A1
(en)
|
2017-02-28 |
2020-02-13 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EP3641812A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
|
AU2018292618A1
(en)
|
2017-06-27 |
2019-12-19 |
Novartis Ag |
Dosage regimens for anti-TIM-3 antibodies and uses thereof
|
|
EP3652209A2
(en)
|
2017-07-11 |
2020-05-20 |
Compass Therapeutics LLC |
Agonist antibodies that bind human cd137 and uses thereof
|
|
KR20250025039A
(ko)
|
2017-07-20 |
2025-02-20 |
노파르티스 아게 |
항-lag-3 항체의 투여 요법 및 그의 용도
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
AU2018368731A1
(en)
|
2017-11-16 |
2020-05-14 |
Novartis Ag |
Combination therapies
|
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
AR114294A1
(es)
|
2017-11-30 |
2020-08-19 |
Grifols Diagnostic Solutions Inc |
Inmunoensayos y proteínas de diseño para la monitorización de tratamientos con anticuerpos contra los inhibidores de puntos de control inmunológicos pd-1 y pd-l1
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
CA3090249A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
EP3790900A1
(en)
|
2018-05-09 |
2021-03-17 |
Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. |
Antibodies specific to human nectin4
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
AU2019272575A1
(en)
|
2018-05-21 |
2020-12-10 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by NK cells
|
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
AU2019284911A1
(en)
|
2018-06-13 |
2020-12-17 |
Novartis Ag |
BCMA chimeric antigen receptors and uses thereof
|
|
US20210238268A1
(en)
|
2018-06-19 |
2021-08-05 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
MX2021005594A
(es)
|
2018-11-13 |
2021-10-22 |
Compass Therapeutics Llc |
Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
|
|
JP2022513255A
(ja)
|
2018-12-20 |
2022-02-07 |
ノバルティス アーゲー |
ＨＤＭ２－ｐ５３相互作用阻害剤とＢＣＬ２阻害剤との組み合わせ及び癌を処置するためのその使用
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP3908372A1
(en)
|
2019-01-13 |
2021-11-17 |
Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. |
Antibodies specific to human nectin-2
|
|
ES2982474T3
(es)
|
2019-02-15 |
2024-10-16 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
ES3032659T3
(en)
|
2019-02-15 |
2025-07-23 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN119661722A
(zh)
|
2019-02-21 |
2025-03-21 |
马伦戈治疗公司 |
结合t细胞相关癌细胞的多功能分子及其用途
|
|
EP3927747A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
US20220088075A1
(en)
|
2019-02-22 |
2022-03-24 |
The Trustees Of The University Of Pennsylvania |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
PH12021552414A1
(en)
|
2019-03-29 |
2022-07-25 |
Atarga Llc |
Anti fgf23 antibody
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
CN114786680A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
Tim-3抑制剂及其用途
|
|
CA3163104A1
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
MX2022007759A
(es)
|
2019-12-20 |
2022-07-19 |
Novartis Ag |
Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
|
|
GB2609554B
(en)
|
2020-01-03 |
2025-08-20 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|
|
EP4090335A1
(en)
|
2020-01-17 |
2022-11-23 |
Novartis AG |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
US20210222244A1
(en)
|
2020-01-17 |
2021-07-22 |
Becton, Dickinson And Company |
Methods and compositions for single cell secretomics
|
|
BR112022016633A2
(pt)
|
2020-02-27 |
2022-12-13 |
Novartis Ag |
Métodos para produzir células que expressam receptor de antígeno quimérico
|
|
US20230183342A1
(en)
|
2020-04-06 |
2023-06-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies to nkp46 and constructs thereof for treatment of cancers and infections
|
|
MX2022015852A
(es)
|
2020-06-23 |
2023-01-24 |
Novartis Ag |
Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
|
|
PH12023550015A1
(en)
|
2020-07-16 |
2024-03-11 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
WO2022044010A1
(en)
|
2020-08-26 |
2022-03-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
US20240002509A1
(en)
|
2020-11-06 |
2024-01-04 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
|
CA3198447A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
|
|
KR20230159823A
(ko)
|
2021-02-11 |
2023-11-22 |
넥틴 테라퓨틱스 리미티드 |
Cd112r에 대한 항체 및 이의 용도
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
EP4405396A2
(en)
|
2021-09-20 |
2024-07-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
US20250034559A1
(en)
|
2021-11-17 |
2025-01-30 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2023105528A1
(en)
|
2021-12-12 |
2023-06-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to ceacam1
|
|
TW202342548A
(zh)
|
2022-02-07 |
2023-11-01 |
美商威特拉公司 |
抗獨特型(anti-idiotype)抗體分子及其用途
|
|
US20250092158A1
(en)
|
2022-02-07 |
2025-03-20 |
Yeda Research And Development Co. Ltd. |
Humanized anti quiescin suefhydrye oxidase 1 (qsox1) antibodies and uses thereof
|
|
AR129136A1
(es)
|
2022-04-26 |
2024-07-17 |
Novartis Ag |
Anticuerpos multiespecíficos que se dirigen a il-13 e il-18
|
|
EP4522757A2
(en)
|
2022-05-13 |
2025-03-19 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
TW202435912A
(zh)
|
2022-08-03 |
2024-09-16 |
美商航海家醫療公司 |
用於穿過血腦屏障之組合物及方法
|
|
KR20250139898A
(ko)
|
2022-11-10 |
2025-09-23 |
페임웨이브 리미티드 |
호중구 세포외 트랩 (net) 매개 활성 억제를 위한 항암배아항원 관련 세포 부착 분자 1 (ceacam1) 항체
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|